It's a "technology" in search of "potential" partners. There is no FDA review because there is no product to review. But first, as with any technology, it will need a valid and enforceable patent. There, the deck is stacked against them. There are no products. Good luck playing patent troll.
I indicated that the 8K's don't show this. Go back and re-read the 8K's and I'm correct. You cited a 13D filing which is not where one would expect to see this because 13D's report beneficial ownership. According to the 8K's, Dolfin now has some unregistered shares, not a smart move because they cannot be traded as they are not registered. Yikes.
Sorry Ig, your fantasy is incorrect. The original $750K note and the current $925K note are convertible into common but the common shares have not been registered and cannot be converted until registered. Go back and re-read the 8K's again. It seems it's enough rope for TBIO to hang itself and force a liquidation of the assets. And when there is a liquidation, the common shareholders take last. That's why the common is worthless. So where are all of those "potential" partners, not bellying up to the bar, eh?
Now that's really looking forward, listing "potential" partners. So can I list "potential" girlfriends, starting with Kate Upton? I have about as much chance of landing Kate Upton as a girlfriend as TBIO has of landing a "potential" partner as a real partner. Credibility is a such fleeting thing.
You've asked a question none of us can answer. CTIX cannot answer it either. Was the Seahawks win on Sunday a fluke? We all have our opinions. It gets to the point I've been constantly making about the management of CTIX, the information is great for the patient and I'm happy for the patient, but it doesn't come anywhere close to the level of clinical evidence to mitigate risk for the drug. And mitigating the risk of clinical failure for each drug is the job that CTIX management is supposed to be doing, not trying to play a stock price manipulation game, bowing to the self-appointed gods of Wall Street with sensationalist press releases, like todays or like the over-hyped December-to-remember press release last month. It shows CTIX management is simply playing the superficial (as opposed to substantive) Wall Street game to getting a pop in the stock price from sensationalism rather than trying to build long term value to benefit investors (as opposed to traders).
Oh and GO Hawks!
I'll answer your questions:
1. Who says the patents are invalid? The "potential" partners and the US Patent Office.
2. "I think Kirk has plenty of money." So what? So does Paul Allen and he also owns the Seahawks. But why does having money mean that an investor should buy a stock with worthless common? If the bull thesis is that the largest controlling shareholder has plenty of money, that is one absurd and shrill reason. By that reason you should all be rooting for the Seahawks on Sunday.
It's commonly called over-promising and under-delivering, a sign of poor management. That's why I posted (at the time of the "momentous December" press release) how poor management is for issuing such a stupid press release. And for that I was erroneously called a basher. Let's vote out the Board for supporting such idiotic management. As I've constantly been posting, I've invested for the assets but didn't go bigger (as a percentage of my meager portfolio) due to weak management. If management is improved by the Board, I'll add. But as long as management keeps shooting itself in the foot, I'll hold until long term cap gain. The purpose of these boards, in my opinion, is to help organize shareholders to throw out poor management when the assets are valuable, like activist hedge funds. But all I see are religious "beliefs" kinds of posting.
Yo, NYC Asian-American, I said "All of my holdings in this sector are selling off. " I don't own (nor short) adxs. Statement was correct at the time it was written.
west coast German-American
Folks, You need to expand your universe well beyond CTIX and look at the overall sector. All of my holdings in this sector are selling off. Why? Likely because the JPM conference is about to end so the hype stream is also ending. CTIX gave a particularly poor presentation with nothing new. Highlighting a patient who dropped out of a study was a particularly dumb move and it shows a lack of anything better. Many other companies also were compelled to provide an "update" but had nothing new to say. Those companies that provided their actual news timed for the conference got a big bump up in their stock price (see, for example, ZIOP, which I shorted yesterday because the "news" was stupid). Look at my favorite short, JUNO. I just covered today, down 14 points in less than a week. With CTIX, I'm still holding long because I'm still several months away from a long term gain with a $1.65 basis. But as I've been posting, the management of this group stinks and is spending too much energy trying to provide a hype stream to its retail shareholder base. In my opinion, they should simply shut up with their credibility-destroying hyped-up faux press releases and focus on adding value to the assets by financing and conducting clinical trials and seeking out partner and perhaps government grant financing.
Patent trolls, even failed patent trolls like TBIO, don't have "potential partners." If your patents are invalid or don't claim what others are doing, you don't have any revenue. Or you have to pay big bucks to law firms to sue your "potential partners" for patent infringement. But oops, wait a minute, TBIO doesn't have big bucks, in fact they don't have any bucks. So no law suits only stupid press releases that mean nothing.
If the patents were so good, there would have been licenses signed by now. Or if the law suit win was a slam dunk, law firms would sign up to take the case on contingency. But since there is neither, we all know it is smoke and mirrors while time is ticking off the clock until BK filing and all of the common shares are worthless.
Boo hoo Herbie, you're going to need a new client to rip off.
Today's press release announces the launching of a "technology." Say What? How does one launch a technology? Launching a product, yes, but a technology, no. In other words, this is the last gasp of a failed patent troll business. No one cares about a bunch of invalid patents, no matter what trademark name is used.
Genius Herbie, mention the biggest loser company in the portfolios of Kirk and Douglas. That means what? Absolutely nothing. So Herbie, since you're the hired PR troll, who bought the $750K controlling note that rendered the common shares worthless? Was it Kirk or Douglas or both? We know this much, both Kirk and Douglas shares are now worth less than half of their purchase price. Genius investors, eh?
So whoever bought the $750K note essentially takes the assets above the common shareholders. The money will only get this sorry company to the end of the month or mid Feb at the latest. I wonder if Kirk is not in complete control of the assets and will do with them as he wishes. That means the common longs will be left with goose-eggs even if the assets are sold off without BK. Isn't Kirk originally a lawyer? Me thinks something is rotten in Omaha.
CAR's inserted into autologous T cells (meaning taken individually from each patients and then transfected with a CAR construct) is phenomenally expensive and a last resort therapy, much like bone marrow transplantation. Is this a viable economic model? Ask DNDN (another company with an autologous transplant product) shareholders, currently BK. And for the record, I went short that one in the upper 40's and unfortunately covered too early.
But I disagree with the part about a combination with the BLRX asset. Immunotherapy is not likely to be combined with a chemical chemotherapy product. The BLRX asset will have to stand or fall on its own merits and those merits (or lack thereof) are what Novartis will look at to determine whether or not to add it to its oncology portfolio of products.
Yikes, if today's spike is due to this "news" it will once again show how ignorant investors are regarding the pharmacology of "small" pharmas. Yes Novartis has the rights to the University of Penn CAR (chimeric antigen receptor) technology that is used in early clinical trials to treat some leukemia and has shown some significant remission rates, albeit at a cost of significant and life-threatening cytokine storm side effects. But this does not relate to BLRX.
My preference as an investor is to invest in (go long) those companies with under-valued assets (as determined by Wall Street) and go short those over-hyped assets that, in my opinion, are being pumped by investment banks and VCs while hoping that investors take their word for it and don't do their technical and patent due diligence. So what does that mean for specific stocks? I'm long BLRX and I about to jump in (sort of like a polar bear swim on New Years Day) to short JUNO (but I'm trying to build the courage to do so right now, so tell me I'm an idiot so help give me more courage). I do my own due diligence and I have both scientific and legal training.
Ben is my middle name but I have no clue who you're referring to. And the original poster needs to check his or her calendar for the week of JP Morgan. I guess hearing the truth is not pleasant for those of you living in FantasyLand, a bit south of SF. Hey check out CEMP tonight! Another score for my anti-infective portfolio. Now we need CTIX to at least hold on and not drop in the next 5 months. Need to make up for some of my energy stocks.
BFD, the conference and the ancillary events, like the biotech showcase, are nothing more than a quickie meat market and speed dating with many more sellers (like CTIX) than buyers (like Pfizer). But it this is announced, it is designed to fool the naïve retail investors but the institutions don't bother. Since this has nearly a half a billion market cap, it needs much more institutional investors who are not as scared as I am about the market cap. If I sell now, I pay 40% tax on the gain. If I sell in 5 months or so, it is about 20%. But I'm concerned that CTIX is not making the required moves to the Nasdaq and instead throwing hyped up nonsense to its retail shareholder base rather than something substantive. In SF in a couple of weeks, the company cannot say anything it hasn't already released to the shareholders under Rule FD and I don't think Leo is stupid enough to violate that rule. Moreover, his retail following will not be in SF (I will be). The key comes during the speed dating sessions, not some "presentation" with the usual corporate slide deck. And those are not public. But there will be boatloads of clinical stage drugs looking for sugar daddies to fund further development. Don't get your hopes up. I don't see CTIX as the belle of the ball.
Have expressed similar concerns and have been boo'd by the religious zealots on this board. Look at the buyout prices of Trius and Durata. And CTIX has not yet started phase 3. It is nearly priced to perfection. I'm happy with the performance but I have an average basis of $1.65 and I bought it during the April-June time period 2014 so I hoping to avoid a crash until June 2015 so I can take the gain as long term.
Who gives a flying fig about the shorts? I don't care. I like my long term position in ZGNX (long) and hope to pay boat-loads of taxes on the long term gains. As for short term gains (where I'll be paying 40+%) I just shorted JUNO. $4Bil is stupid (in my opinion) when there is a wee bit of early phase data only with pediatric leukemias (not solid tumors), a big patent fight against Novarits (who is ahead of Juno in the clinic with their work at Penn) and at least 25 other companies working in the CAR space.
So save all of this shrill nonsense being posted as I don't even read it.